Aspira Women’s Health Webinar: Ovarian Cancer Risk Assessments Utilizing Multivariant Index Assay
|DATE:||August 24, 2022|
|TIME:||12:00 PM EDT|
About The Event
This event will be hosted by Aspira Women’s Health executives Nicole Sandford, CEO, Dr. Ryan Phan, PhD, Chief Scientific Officer/Chief Operating Officer, and Dr. Charles Dunton, MD, and will feature presentations from Key Opinion Leaders (KOLs) Nicole E. Williams, MD, FACOG, FACS (The Gynecology Institute of Chicago) and Gerard P. Reilly, MD (Director of Clinical Research and Innovation, Axia Women’s Health).
Dr. Williams will discuss how Aspira’s OVA1Plus® test leads to improved health outcomes for women with adnexal masses by helping physicians to stratify patients planned for surgery based on their risk of ovarian cancer. OVA1Plus is a combination of two FDA-cleared multivariate index assays that combines the results of biomarkers and proprietary algorithms to provide a malignancy risk index to physicians.
Dr. Reilly was a co-author of a recently published paper, Analytical Validation of a Deep Neural Network Algorithm for the Detection of Ovarian Cancer. He will discuss how Aspira’s soon-to-be-launched OVAWatchTM multivariate index assay diagnostic risk assessment may benefit women with pelvic masses who are not planned for surgery.
A live question and answer session will follow.